Seres Therapeutics (NASDAQ:MCRB) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $14.41 and traded as low as $7.14. Seres Therapeutics shares last traded at $7.46, with a volume of 76,902 shares changing hands.

Analyst Ratings Changes

MCRB has been the topic of several recent research reports. Chardan Capital reaffirmed a "neutral" rating and set a $6.00 target price (up previously from $1.25) on shares of Seres Therapeutics in a report on Thursday, May 8th. Wall Street Zen raised shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 9th. Finally, The Goldman Sachs Group reduced their target price on shares of Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a report on Friday, March 14th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $73.67.

Seres Therapeutics Trading Down 3.4%

The company has a market cap of $64.97 million, a P/E ratio of -32.35 and a beta of 2.89. The company's fifty day moving average is $10.45 and its 200 day moving average is $14.18.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($1.57). Analysts anticipate that Seres Therapeutics, Inc. will post -0.38 EPS for the current year.

Institutional Investors Weigh In On Seres Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Millennium Management LLC grew its holdings in Seres Therapeutics by 77.2% in the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock worth $1,505,000 after acquiring an additional 788,762 shares during the last quarter. Geode Capital Management LLC grew its holdings in Seres Therapeutics by 8.8% in the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company's stock worth $1,256,000 after acquiring an additional 121,793 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in Seres Therapeutics by 15.7% in the 1st quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock worth $760,000 after acquiring an additional 147,671 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Seres Therapeutics by 15.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company's stock worth $720,000 after acquiring an additional 117,107 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Seres Therapeutics by 20.4% in the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock worth $218,000 after acquiring an additional 44,461 shares during the last quarter. Institutional investors own 59.34% of the company's stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.